BeiGene, Ltd.
https://www.beigene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BeiGene, Ltd.
Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- MapKure, LLC